Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5891570 | Bone | 2011 | 6 Pages |
Abstract
⺠Ibandronate quarterly 3 mg IV injection is well tolerated in women with PMO and at risk for renal disease. ⺠IV ibandronate can be used even in patients with pre-existing hypertension or diabetes mellitus. ⺠Ibandronate injection can be administered safely in the primary care setting. ⺠IV ibandronate showed comparable safety to oral alendronate in women with postmenopausal osteoporosis (PMO) at increased risk for renal disease.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Developmental Biology
Authors
Paul D. Miller, Sergio Ragi-Eis, Carlos Mautalen, Francisco Ramirez, Iris Jonkanski,